Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. (14th August 2022)

• Record Type: Journal Article
• Authors: Tomonari, Tetsu; Tani, Joji; Sato, Yasushi; Tanaka, Hironori; Tanaka, Takahiro; Taniguchi, Tatsuya; Asahiro, Morishita; Okamoto, Koichi; Sogabe, Masahiro; Miyamoto, Hiroshi; Muguruma, Naoki; Masaki, Tsutomu; Takayama, Tetsuji
• Is Part Of: Cancer medicine. Volume 12:Number 3(2023)
• Page Start: 2646
• Page End: 2657
• Publication Date: 2022-08-14
• Subjects: atezolizumab -- bevacizumab -- hepatocellular carcinoma; 616.994005
• DOI: 10.1002/cam4.5145
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Aim: We analyzed the association between the modified albumin–bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u‐HCC). Methods: In this retrospective observational study, we included 71 u‐HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment. Results: According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression‐free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second‐line treatment with multi‐targeted agents was also significantly higher in the mALBI 1+2a group. Conclusions: In real‐world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u‐HCC patients with mALBI 1+2a. Abstract : Our data suggest that Atezo+Bev treatment has a good anti‐tumor effect on mALBI 1+2a and a reasonable transition rate to the subsequent molecular‐targeted agents treatment.